BMS CA 209-331-001 An Open label, Randomized Phase 3 Study of Nivolumab or Chemo

Administered By

Duke Cancer Institute

Contributors

Ready, Neal Edward Principal Investigator

Start/End

July 1, 2015 - June 30, 2022